About Ecsponent Biotech
Ecsponent Biotech is a biotechnology hub transacting in cellular therapies, treatments and research in Southern Africa. As one of the specialised divisions in the Ecsponent private equity stable, Ecsponent Biotech provides the possibility of significant investment returns in line with Ecsponent’s approach to invest in companies with a technical and innovative edge.
The biotech industry is arguably still in the early stages of the innovation cycle with estimated development timelines of 10 to 15 years, there is substantial evidence that biotech is a significant growth area across the various disciplines of medical technology. This is where the investment opportunity presents itself.
Ecsponent has invested in a number of international and local brands that meet our strong future-based investment requirements and combines the technical excellence of leading biotech organisations with Ecsponent’s local business expertise. These investments include Cryo-Save (Europe’s largest stem cell bank), Salveo Swiss Biotechnology (Geneva-based leader in predictive medicine), Lazaron Biotechnology, South Africa’s first umbilical cord stem cell bank, founded in 2005.
Complementing the cord blood and tissue stem cell storage options offered, Ecsponent Biotech has developed a range of new services that have the potential to give parents peace of mind about their children’s health and future, or can even save their lives.
In addition to its investment in regenerative medicine, Ecsponent Biotech leverages the infra-structure created by these investments to create biopharmaceutical products, i.e. treatment products manufactured in, extracted from, or semi-synthesised from biological sources.
The first of these biopharmaceutical products is Ocu-Drops – an autologous eye serum that treats severe ocular surface disorders. Read more here…
Cryo-Save is a part of the Cryo-Save Group that was established in 2000, has been active in the stem cell industry for more than 15 years and is the largest private family stem cell storage bank in Europe and Africa.
In 2011, Ecsponent Limited and Cryo-Save’s holding company, Esperite, entered into a joint venture to acquire the rights for Cryo-Save in South Africa. Cryo-Save’s high-tech laboratory in Pretoria is the largest of its kind in the whole of Africa, providing top level umbilical cord stem cell processing and storage services.
Cryo-Save South Africa offers both local and international storage options in either South Africa or Europe, for both cord blood and cord tissue. Lazaron Biotechnologies is now administered by Cryo-Save South Africa.
Lazaron Biotechnologies (SA) Ltd is South Africa’s oldest and most experienced umbilical cord blood stem cell storage service. The company was founded in 2005 after the development of our technology at the Stellenbosch University by well-known stem cell researcher, Professor Daniel Barry, and his research team. Lazaron is now administered by Cryo-Save South Africa.
Salveo Swiss Technologies was introduced to the South African market following a joint venture agreement between Ecsponent Limited and international biotechnology group, Esperite. The group acquired the rights for Salveo Swiss Biotechnology to further entrench the two shareholders’ dominance of the local market and to offer South African parent a world-class service stem cell storage that is both affordable and sustainable.
Headquartered in Switzerland and with a footprint in over 40 countries across three continents, Esperite is a leader in the field of cryopreservation.
Due to its association with Esperite, Salveo is governed by the protocols and procedures of Europe’s largest stem cell bank and the renowned Swiss quality ingrained in every aspect of the business to ensure consistent quality.